Pfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In Kids

Verified Media
· Views 27

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Monday that they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization or EUA of a 10-g booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.

The request for EUA of the vaccine in this age group is supported by safety and immunogenicity data from the companies' bivalent Omicron BA.1-adapted vaccine, non-clinical and manufacturing data from the companies' 10-g bivalent Omicron BA.4/BA.5-adapted vaccine, and pre-clinical data from Omicron BA.4/BA.5-adapted vaccine in their decision.

The companies will also submit an application to extend the Omicron BA.4/BA.5-adapted bivalent vaccine marketing authorization to include children ages 5 through 11 years to the European Medicines Agency or EMA in the coming days.

Pfizer and BioNTech have also initiated a Phase 1/2/3 study NCT05543616 (C4591048) to evaluate the safety, tolerability, and immunogenicity of different doses and dosing regimens of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age.

The pediatric study, consistent with regulatory guidance, follows a previous Phase 1/2/3 trial involving these age groups that demonstrated the original Pfizer-BioNTech COVID-19 Vaccine is well-tolerated and offers a high level of protection against COVID-19, measured at a time when the Omicron BA.2 strain was highly prevalent.

The Pfizer-BioNTech COVID-19 Vaccine is based on BioNTech's proprietary mRNA technology. It was developed by both BioNTech and Pfizer.

For More Such Health News, visit

Business News

Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.

FOLLOWME Trading Community Website:

If you like, reward to support.


No comment on record. Start new comment.